XFOR · NASDAQ
X4 Pharmaceuticals (XFOR) Stock Price & Fundamentals
X4 Pharmaceuticals (XFOR) closed at $363.86 on Oct 9, 2026, down 1.22% from the previous close of $368.36.
Share price, past year
1Y +31.91%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $363.86 |
| Sep 30, 2026 | $373.15 |
| Aug 31, 2026 | $351.32 |
| Jul 31, 2026 | $347.88 |
| Jun 30, 2026 | $353.32 |
| May 29, 2026 | $335.13 |
| Apr 30, 2026 | $319.05 |
| Mar 31, 2026 | $303.41 |
| Feb 27, 2026 | $308.57 |
| Jan 30, 2026 | $284.89 |
| Dec 31, 2025 | $300.56 |
| Nov 28, 2025 | $273.23 |
| Oct 31, 2025 | $281.70 |
Key statistics
- Market cap
- $34.97B
- P/E (TTM)
- 286.5
- EPS (TTM)
- $1.27
- Revenue (TTM)
- $8.80M
- Net income (TTM)
- −$90.14M
- Shares outstanding
- 96.1M
- Dividend yield
- —
- 52-week range
- $267.34 – $373.15
X4 Pharmaceuticals's market cap is $34.97B, based on a share price of $363.86 and 96.1M shares outstanding as of Jun 30, 2026.
Financials
X4 Pharmaceuticals reported revenue of $6.50M for fiscal 2025, up 150.00% from fiscal 2024.
X4 Pharmaceuticals reported a net loss of $79.20M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 8 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $6.50M | +150.0% | −$79.20M | −1,218.5% | −$1.87 | — |
| FY2024ended Dec 31, 2024 | $2.60M | — | −$37.45M | −1,440.4% | −$5.59 | −$131.23M |
| FY2023ended Dec 31, 2023 | $0.00 | — | −$101.17M | — | −$17.07 | −$96.57M |
| FY2022ended Dec 31, 2022 | $0.00 | — | −$93.87M | — | −$45.65 | −$77.21M |
| FY2021ended Dec 31, 2021 | $0.00 | −100.0% | −$88.70M | — | −$119.82 | — |
| FY2020ended Dec 31, 2020 | $3.00M | — | −$62.13M | −2,071.0% | −$92.79 | — |
| FY2019ended Dec 31, 2019 | $0.00 | — | −$52.81M | — | −$139.04 | — |
| FY2018ended Dec 31, 2018 | $0.00 | — | −$33.29M | — | −$2,376.88 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $2.40M | −$16.16M | −$0.13 |
| Q1 FY2026ended Mar 31, 2026 | $2.50M | −$20.24M | −$0.16 |
| Q4 FY2025ended Dec 31, 2025 | $2.33M | −$23.93M | $2.25 |
| Q3 FY2025ended Sep 30, 2025 | $1.57M | −$29.82M | −$0.69 |
| Q2 FY2025ended Jun 30, 2025 | $1.70M | −$25.74M | −$3.47 |
| Q1 FY2025ended Mar 31, 2025 | $900.00K | $282.00K | $0.04 |
| Q4 FY2024ended Dec 31, 2024 | $1.48M | −$39.82M | −$5.91 |
| Q3 FY2024ended Sep 30, 2024 | $560.00K | −$36.70M | −$5.48 |
Company profile
- Name
- X4 Pharmaceuticals, Inc
- Ticker
- XFOR
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 61 North Beacon Street, 4th Floor, Boston, MA 02134
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001501697
Recent SEC filings
- Oct 8, 2026
- Sep 9, 2026
- Sep 8, 2026
- Aug 6, 2026
- Jul 1, 2026
- May 12, 2026
- May 6, 2026
- Mar 17, 2026
Frequently asked questions
What is X4 Pharmaceuticals's stock price?
X4 Pharmaceuticals (XFOR) closed at $363.86 on Oct 9, 2026, down 1.22% from the previous close of $368.36.
What is X4 Pharmaceuticals's market cap?
X4 Pharmaceuticals's market cap is $34.97B, based on a share price of $363.86 and 96.1M shares outstanding as of Jun 30, 2026.
How much revenue does X4 Pharmaceuticals make?
X4 Pharmaceuticals reported revenue of $6.50M for fiscal 2025, up 150.00% from fiscal 2024.
What is XFOR's P/E ratio?
X4 Pharmaceuticals's price-to-earnings ratio is 286.5, based on trailing twelve-month diluted EPS of $1.27.
Does X4 Pharmaceuticals pay a dividend?
X4 Pharmaceuticals's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from X4 Pharmaceuticals, Inc's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures